Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL)
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Embraced with apolipoproteins (Apo) B and Apo E, triglyceride-enriched very-low-density lipoprotein (VLDL) is secreted by the liver into circulation, mainly during post-meal hours. Here, we present a brief review of the physiological role of VLDL and a systemic review of the emerging evidence supporting its pathological roles. VLDL promotes atherosclerosis in metabolic syndrome (MetS). VLDL isolated from subjects with MetS exhibits cytotoxicity to atrial myocytes, induces atrial myopathy, and promotes vulnerability to atrial fibrillation. VLDL levels are affected by a number of endocrinological disorders and can be increased by therapeutic supplementation with cortisol, growth hormone, progesterone, and estrogen. VLDL promotes aldosterone secretion, which contributes to hypertension. VLDL induces neuroinflammation, leading to cognitive dysfunction. VLDL levels are also correlated with chronic kidney disease, autoimmune disorders, and some dermatological diseases. The extra-hepatic secretion of VLDL derived from intestinal dysbiosis is suggested to be harmful. Emerging evidence suggests disturbed VLDL metabolism in sleep disorders and in cancer development and progression. In addition to VLDL, the VLDL receptor (VLDLR) may affect both VLDL metabolism and carcinogenesis. Overall, emerging evidence supports the pathological roles of VLDL in multi-organ diseases. To better understand the fundamental mechanisms of how VLDL promotes disease development, elucidation of the quality control of VLDL and of the regulation and signaling of VLDLR should be indispensable. With this, successful VLDL-targeted therapies can be discovered in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“In highly progressive cancer cells, lipid biosynthesis and uptake were also increased [219,220].”
BackgroundKhovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., & Grunfeld, C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r300019-jlr200 · Cited by 1,481 · cited 1×
“In contrast, multiple cytokines can elevate VLDL levels, such as interleukin (IL)-1, IL-2, and IL-6 [203].”
Anoikis molecular pathways and its role in cancer progression
Paoli, P., Giannoni, E., & Chiarugi, P. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.026 · Cited by 1,160
Ectopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
Shulman, G. I. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1011035 · Cited by 1,126 · cited 1×
“Subjects with insulin resistance have a reduced ability to store lipids in adipose tissue, and are therefore prone to hyperlipidemia and ectopic lipid accumulation [42,94].”
BackgroundNordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis
Nomura, D. K., Long, J. Z., Niessen, S., Hoover, H. S., Ng, S.-W., & Cravatt, B. F. (2010) · Cell · doi:10.1016/j.cell.2009.11.027 · Cited by 1,002 · cited 1×
“In highly progressive cancer cells, lipid biosynthesis and uptake were also increased [219,220].”
BackgroundGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979 · cited 1×
“Clinical observations have shown that cardiovascular risk is associated with higher Apo B levels and lower Apo C-III of VLDL [3,104,159].”
Splanchnic lipolysis in human obesity
Nielsen, S., Guo, Z., Johnson, C. M., Hensrud, D. D., & Jensen, M. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21047 · Cited by 933
Fabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
Regulation of intestinal lipid metabolism: current concepts and relevance to disease
Ko, C.-W., Qu, J., Black, D. D., & Tso, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0250-7 · Cited by 510
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
Choi, S. H., & Ginsberg, H. N. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.04.007 · Cited by 418 · cited 1×
“In subjects with greater body weight and insulin resistance, Apo C-III of VLDL is increased, which enhances the uptake of VLDL by hepatocytes [20,63,64].”
BackgroundBianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385 · cited 4×
“Similar to breast cancer, VLDL also affects HCC development and progression.”
BackgroundInfluentialCombined oral contraceptives: the risk of myocardial infarction and ischemic stroke
Roach, R. E. J., Helmerhorst, F. M., Lijfering, W. M., Stijnen, T., Algra, A., & Dekkers, O. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011054.pub2 · Cited by 299 · cited 1×
“For women of reproductive age, elevated cardiovascular risk is only observed with high-dose estrogen combined with oral contraceptives [136].”
BackgroundMarston, N. A., Giugliano, R. P., Melloni, G. E. M., Park, J.-G., Morrill, V., Blazing, M. A., Ference, B., Stein, E., Stroes, E. S., Braunwald, E., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.5083 · Cited by 262 · cited 2×
“Increased Apo C-III, Apo E-III, and E-IV of VLDL in MetS exhibit reduced LPL activity and function [8,27,104,105].”
BackgroundLipid and Lipoprotein Metabolism in Microglia
Loving, B. A., & Bruce, K. D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00393 · Cited by 255
Doi, H., Kugiyama, K., Oka, H., Sugiyama, S., Ogata, N., Koide, S.-I., Nakamura, S.-I., & Yasue, H. (2000) · Circulation · doi:10.1161/01.cir.102.6.670 · Cited by 227 · cited 2×
“Except for lipid transportation and metabolism, VLDL can promote thrombin generation and inhibit fibrinolysis [54–56], and can bind coagulation factors VII and X [57,58].”
BackgroundVarbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.234146 · Cited by 209
The case of visceral fat: argument for the defense
Klein, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422028 · Cited by 206
Kawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F. W., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.105.591743 · Cited by 206
Postprandial metabolism of meal triglyceride in humans
Lambert, J. E., & Parks, E. J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.01.006 · Cited by 182
Balling, M., Afzal, S., Varbo, A., Langsted, A., Davey Smith, G., & Nordestgaard, B. G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.610 · Cited by 175 · cited 2×
“Other underlying mechanisms include pro-atherogenic effects, [27,33,37,41,47,157] and promotion of thromboembolism with hypercoagulability [54,56,158].”
BackgroundCohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170
Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies
Corona, G., Rastrelli, G., Di Pasquale, G., Sforza, A., Mannucci, E., & Maggi, M. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.04.641 · Cited by 138 · cited 1×
“Regarding sex hormones, testosterone does not affect VLDL metabolism [53,126,127].”
BackgroundWu, T., Yang, L., Jiang, J., Ni, Y., Zhu, J., Zheng, X., Wang, Q., Lu, X., & Fu, Z. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.11.049 · Cited by 126 · cited 1×
“The most commonly used therapy for patients with autoimmune diseases is steroids, which have been proven to increase plasma VLDL concentrations [111,147,148,211].”
BackgroundGiordano, R., Picu, A., Marinazzo, E., D’Angelo, V., Berardelli, R., Karamouzis, I., Forno, D., Zinnà, D., Maccario, M., Ghigo, E., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04055.x · Cited by 122
Effects of VLDL and remnant particles on platelets.
Olufadi, R., & Byrne, C. D. (2006) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000093221 · Cited by 111
Ren, J., Grundy, S. M., Liu, J., Wang, W., Wang, M., Sun, J., Liu, J., Li, Y., Wu, Z., & Zhao, D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.020 · Cited by 111 · cited 1×
“A large Chinese cohort study showed an association between elevated VLDL concentration and coronary heart disease [154].”
BackgroundVLDL triglyceride kinetics in lean, overweight, and obese men and women
Mittendorfer, B., Yoshino, M., Patterson, B. W., & Klein, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1500 · Cited by 108
Goudriaan, J. R., Santo, S. M. S. E., Voshol, P. J., Teusink, B., van Dijk, K. W., van Vlijmen, B. J. M., Romijn, J. A., Havekes, L. M., & Rensen, P. C. N. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400009-jlr200 · Cited by 100
Leeb, C., Eresheim, C., & Nimpf, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.529271 · Cited by 99 · cited 2×
“Reelin depletion is regarded as an early phenomenon in Alzheimer’s disease [172,173], whereas clusterin promotes amyloid beta clearance [32,174,175].”
BackgroundDeterminants of VLDL-triglycerides production
Nielsen, S., & Karpe, F. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283544956 · Cited by 94
Reelin depletion is an early phenomenon of Alzheimer's pathology
Herring, A., Donath, A., Steiner, K. M., Widera, M. P., Hamzehian, S., Kanakis, D., Kölble, K., ElAli, A., Hermann, D. M., Paulus, W., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-112069 · Cited by 92 · cited 1×
“Reelin depletion is regarded as an early phenomenon in Alzheimer’s disease [172,173], whereas clusterin promotes amyloid beta clearance [32,174,175].”
BackgroundThe Reelin Receptors Apolipoprotein E receptor 2 (ApoER2) and VLDL Receptor
Dlugosz, P., & Nimpf, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103090 · Cited by 91 · cited 4×
“VLDL can be taken up by VLDLR, which is expressed abundantly in adipocytes, cardiomyocytes, and the endothelium [13,30,31].”
BackgroundInfluentialMarchand, G. B., Carreau, A.-M., Weisnagel, S. J., Bergeron, J., Labrie, F., Lemieux, S., & Tchernof, A. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00293.2017 · Cited by 73
Alternative macrophages in atherosclerosis: not always protective!
Pourcet, B., & Staels, B. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120123 · Cited by 62
Inancli, S. S., Usluogullari, A., Ustu, Y., Caner, S., Tam, A. A., Ersoy, R., & Cakir, B. (2013) · Endocrine · doi:10.1007/s12020-012-9857-y · Cited by 59
Wang, Y., Lee, A., Lu, L., Ke, L., Chen, W., Dong, J., Lu, J., Chen, Z., Chu, C., Chan, H., et al. (2018) · Aging Cell · doi:10.1111/acel.12792 · Cited by 58 · cited 1×
“The electronegative VLDL has altered lipid content and induces significant apoptosis and senescence of endothelial cells [101,165,166].”
BackgroundMendivil, C. O., Rimm, E. B., Furtado, J., & Sacks, F. M. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000130 · Cited by 48 · cited 3×
“Increased Apo C-III, Apo E-III, and E-IV of VLDL in MetS exhibit reduced LPL activity and function [8,27,104,105].”
BackgroundImpaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease
Poulsen, M. K., Nellemann, B., Stødkilde-Jørgensen, H., Pedersen, S. B., Grønbæk, H., & Nielsen, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3476 · Cited by 39
Independent Effects of Testosterone on Lipid Oxidation and VLDL-TG Production
Høst, C., Gormsen, L. C., Christensen, B., Jessen, N., Hougaard, D. M., Christiansen, J. S., Pedersen, S. B., Jensen, M. D., Nielsen, S., & Gravholt, C. H. (2013) · Diabetes · doi:10.2337/db12-0440 · Cited by 37
Impact of body composition on very-low-density lipoprotein-triglycerides kinetics
Gormsen, L. C., Nellemann, B., Sørensen, L. P., Jensen, M. D., Christiansen, J. S., & Nielsen, S. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90675.2008 · Cited by 32 · cited 1×
“In subjects with type 2 diabetes, the ability of insulin to suppress VLDL production is impaired [89,95], and their postprandial VLDL concentration is elevated, although the clearance rate of postprandial VLDL is similar to that in non-diabetic subjects [46].”
ResultMucinski, J. M., Manrique‐Acevedo, C., Kasumov, T., Garrett, T. J., Gaballah, A., & Parks, E. J. (2020) · Lipids · doi:10.1002/lipd.12244 · Cited by 27
Gentile, M., Iannuzzi, A., Giallauria, F., D’Andrea, A., Venturini, E., Pacileo, M., Covetti, G., Panico, C., Mattiello, A., Vitale, G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051422 · Cited by 21
Nandeesha, H., Keshri, N., Rajappa, M., & Menon, V. (2023) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1839500 · Cited by 17
Cited by
Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD
Kim, S. J., & Hyun, J. (2024) · Molecules and Cells · doi:10.1016/j.mocell.2024.100010 · Cited by 30
Zhang, Y., Jiang, X., Wang, W., Lei, L., Sheng, R., Li, S., Luo, J., Liu, H., Zhang, J., Han, X., et al. (2024) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.124.321076 · Cited by 27
Yang, R., Zhang, J., Yu, X., Yang, G., & Cai, J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae001 · Cited by 12
Metadata
- Authors
- Huang, J.-K., & Lee, H.-C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-13
- Volume
- 23
- Issue
- 8
- Pages
- 4300
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4224066461
- Cited by
- 102
- References
- 46
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.